1. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs 
	Haslam et al., JAMA Netw. Open, 2019; 2(5):e192535.
2. Precision medicine using microbiota 
	Jobin, Science, 2018; 359(6371):32-34
3. The microbiome, cancer, and cancer therapy
	Helmink et al., Nature  Medicine, 2019; 25(3):377-388
4. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage
	Fluckiger, …, Zitvogel et al., Science (2020); 369(6506):936–942
5. 